Arginase inhibitors simultaneously improve vascular function in COPD and enhance antitumor immunity, while nanoparticle-delivered glutaminase blockers attenuate pulmonary fibrosis while curbing cancer progression. The gene discussed is GLS; the disease is pulmonary fibrosis.